BACKGROUND: Little is known about prescription trends in atrial fibrillation (AF) in primary health care in Sweden. OBJECTIVE: The aim was to study time trends in pharmacotherapy, in men and women with AF. We also aimed at studying doctors' adherence to CHADS2 for prescribing warfarin. CHADS2 assesses stroke risk by presence of known risk factors, i.e., congestive heart failure, hypertension, age >75 years, diabetes, previous stroke and transient ischemic attack. METHODS: Data were obtained from primary health care records that contained individual clinical data. In total, 371,036 patients were included in the sample from 2002, and 424,329 patients were included in the sample from 2007. The study population consisted of individuals aged 45+ years who were diagnosed with AF in 2002 (1,330 men and 1,096 women) and 2007 (2,748 men and 2,234 women). The pharmacotherapies prescribed in 2002 and 2007 were analyzed separately in men and women. Logistic regression was used to calculate the association between the CHADS2 score and prescribed warfarin treatment. RESULTS: Selective beta-blockers, anti-coagulant therapy and lipid-lowering drugs were prescribed more frequently in 2007 than in 2002. In 2007, antithrombotic and RAS-blocking agents were prescribed more frequently to men, whereas beta-1 selective beta-blockers were prescribed more frequently to women. There was no consistent association between the CHADS2 score and prescribed warfarin treatment. CONCLUSIONS: Pharmacotherapy of AF has improved over time, though CHADS2 guidelines need to be implemented systematically in primary health care in Sweden to decrease the risk of stroke and improve quality of life in patients with AF.
BACKGROUND: Little is known about prescription trends in atrial fibrillation (AF) in primary health care in Sweden. OBJECTIVE: The aim was to study time trends in pharmacotherapy, in men and women with AF. We also aimed at studying doctors' adherence to CHADS2 for prescribing warfarin. CHADS2 assesses stroke risk by presence of known risk factors, i.e., congestive heart failure, hypertension, age >75 years, diabetes, previous stroke and transient ischemic attack. METHODS: Data were obtained from primary health care records that contained individual clinical data. In total, 371,036 patients were included in the sample from 2002, and 424,329 patients were included in the sample from 2007. The study population consisted of individuals aged 45+ years who were diagnosed with AF in 2002 (1,330 men and 1,096 women) and 2007 (2,748 men and 2,234 women). The pharmacotherapies prescribed in 2002 and 2007 were analyzed separately in men and women. Logistic regression was used to calculate the association between the CHADS2 score and prescribed warfarin treatment. RESULTS: Selective beta-blockers, anti-coagulant therapy and lipid-lowering drugs were prescribed more frequently in 2007 than in 2002. In 2007, antithrombotic and RAS-blocking agents were prescribed more frequently to men, whereas beta-1 selective beta-blockers were prescribed more frequently to women. There was no consistent association between the CHADS2 score and prescribed warfarin treatment. CONCLUSIONS: Pharmacotherapy of AF has improved over time, though CHADS2 guidelines need to be implemented systematically in primary health care in Sweden to decrease the risk of stroke and improve quality of life in patients with AF.
Authors: Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Per E Wändell; Axel C Carlsson; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist Journal: Int J Cardiol Date: 2011-08-17 Impact factor: 4.164
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: A S Go; E M Hylek; K A Phillips; L H Borowsky; L E Henault; Y Chang; J V Selby; D E Singer Journal: Circulation Date: 2000-07-04 Impact factor: 29.690
Authors: Karin M Henriksson; Bahman Farahmand; Saga Johansson; Signild Asberg; Andreas Terént; Nils Edvardsson Journal: Int J Cardiol Date: 2009-01-13 Impact factor: 4.164
Authors: Axel C Carlsson; Per Wändell; Danijela Gasevic; Jan Sundquist; Kristina Sundquist Journal: Int J Cardiol Date: 2015-04-01 Impact factor: 4.164
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist Journal: J Hypertens Date: 2018-09 Impact factor: 4.844
Authors: Scott A Chapman; Catherine A St Hill; Meg M Little; Michael T Swanoski; Shellina R Scheiner; Kenric B Ware; M Nawal Lutfiyya Journal: BMC Health Serv Res Date: 2017-02-11 Impact factor: 2.655
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Sven-Erik Johansson; Jan Sundquist; Kristina Sundquist Journal: Scand Cardiovasc J Date: 2016-08-18 Impact factor: 1.589
Authors: Alberto Pilotto; Pietro Gallina; Massimiliano Copetti; Andrea Pilotto; Francesco Marcato; Anna M Mello; Matteo Simonato; Giancarlo Logroscino; Alessandro Padovani; Luigi Ferrucci; Francesco Panza Journal: J Am Geriatr Soc Date: 2016-06-13 Impact factor: 5.562
Authors: Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Sven-Erik Johansson; Jan Sundquist; Kristina Sundquist Journal: Int J Cardiol Date: 2016-07-09 Impact factor: 4.164